AN2 Therapeutics, Inc. ANTX
Set alert
4.53 USD -0.16 -3.41%
At close · Oct 30
4.53 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
4.31 Day range 4.76
1.03 52-week range 6.28
- YTD
- +297.37%
- 1 year
- +265.32%
- Open
- 4.66
- Prev close
- 4.69
- Mkt cap
- 170.95M
- Vol
- 284.72K
- Avg vol
- 264.57K
- EPS
- -1.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.31
- High
- 4.76
- Forward P/E
- -1.17
- Beta
- -0.22
- Short ratio
- 0.82
- Inst. own
- 52.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 1.22
- 200-d avg
- 1.88
- 1y target
- 2.67
Financial health
Altman Z-Score
12.96 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 3
Valuation
P/E -1.0×
FY 2019 5y median -3.4× FY 2025
P/S 0.0×
FY 2019 5y median 0.0× FY 2025
P/B 0.6×
FY 2019 5y median 1.5× FY 2025
P/FCF -1.2×
FY 2019 5y median -4.4× FY 2025
EV/EBITDA -0.4×
FY 2019 5y median -0.4× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -86.6%
FY 2019 5y median -22.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019 5y median 0.0% FY 2025
ROE -66.3%
FY 2019 5y median -51.9% FY 2025
ROIC -71.6%
FY 2019 5y median -55.8% FY 2025
ROA -56.8%
FY 2019 5y median -46.7% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2019 FY 2025
Operating Income 30.1%
FY 2019 FY 2025
EPS (diluted) 32.6%
FY 2019 FY 2025
Free Cash Flow 39.4%
FY 2019 FY 2025
Financial Health
Current Ratio 6.9×
FY 2019 5y median 8.4× FY 2025
Quick Ratio 6.9×
FY 2019 5y median 8.4× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA 0.6×
FY 2019 5y median 0.6× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31